A cell-type specific targeting of cancer cells with higher levels of EGFR was shown to be possible by coupling an anti-EGFR aptamer with anti-HOTAIR siRNA in a cell line model of triple-negative breast cancer (Wang YL. The gene discussed is EGFR; the disease is triple-negative breast carcinoma.